Subscribe to RSS
Download PDF
DOI: 10.1055/s-0038-1624946
Significance of Renal Visualization during Bone Scanning in Paget’s Disease
Die Bedeutuug der Nierendarstellung in Knochenszintigrammen bei Patienten mit M. PagetPublication History
Received:21 January 1976
Publication Date:
11 January 2018 (online)
Summary
In 17 of 26 patients with extensive, symptomatic Paget’s disease poor renal visualization was noted on bone scanning with 99mTc-diphosphonate. Renal function was normal in all patients. The intensity of the renal image proved to be inversely related to the extent and metabolic activity of the Pagetic process. This finding supports the hypothesis that in Paget’s disease the balance between skeletal and renal extraction of circulating tracer may be displaced in favor of the former.
Siebzehn von 26 Patienten mit fortgeschrittenem, symptomatischem Morbus Paget hatten eine verminderte Nierenradioaktivität im Knochenszintigramm mit 99mTc-Diphosphonat. Die Nierenfunktion aller Patienten war normal. Die Intensität der Nierendarstellung verhielt sich umgekehrt zum Ausmaß und zur metabolischen Aktivität des Morbus Paget. Diese Beobachtung unterstützt die Hypothese, daß bei Morbus Paget das Verhältnis zwischen Knochen- und Nierenextraktion des zirkulierenden Radiopharmakons zugunsten der Knochenaufnahme verschoben ist.
The Paget’s disease treatment program at this institution has been supported by the NIH grants AM-09579 and RR-00645.
-
References
- 1 Subramanian G, McAfee J. G, Bell E. G. et al Technetium 99m-labeled polyphosphate as a skeletal imaging agent. Radiology 1972; 102: 701-704.
- 2 Park C. H, Glassman L. M, Tompson N. L. et al Reliability of renal imaging obtained incidentally in 99mTc-polyphosphate bone scanning. J. Nucl. Med 1973; 14: 534-536.
- 3 Krishnamurthy G. T, Tubis M, Endow J. S. et al Clinical comparison of kinetics of technetium-99m labeled polyphosphate and diphosphonate. J. Nucl. Med 1974; 15: 848-855.
- 4 Sy W. M, Patel D, Faunce H. Significance of absent or faint kidney sign on bone scan. J. Nucl. Med 1975; 16: 454-456.
- 5 Roy A. V. Rapid method for determining alkaline phosphatase activity in serum with thymolphthalein monophosphate. Clin. Chem 1970; 16: 431-436.
- 6 Kivirikko K. I, Laitinen O, Prockop D. J. Modifications of a specific assay for hydroxyproline in urine. Anal. Biochem 1967; 19: 249-455.
- 7 Howarth S. Cardiac output in osteitis deformans. Clin. SeI 1953; 12: 271-275.
- 8 Miller S. W, CastronovoH F. P, Pendergrass P. et al Technetium-99m-labeled diphosphonate bone scanning in Paget’s disease. Amer. J. Roentgenol 1974; 121: 177-183.
- 9 Winter P. F, Johnson P. M. Unpublished data.
- 10 Guncaga J, Lauffenburger T. H, Leutner C. et al. Diphosphonate treatment of Paget’s disease of bone. Horm. Metab. Res 1974; 6: 62-69.
- 11 Khrairi M. R. A, Wellman H. N, Robb J. A. et al Paget’s disease of bone (osteitis deformans): symptomatic lesions and bone scan. Ann. Intern. Med 1973; 79: 348-351.
- 12 DeDeuxchaisnes C. N, Krane S. M. Paget’s disease of bone, clinical and metabolic observations. Medicine (Baltimore) 1964; 43: 233-266.
- 13 Woodhouse N. J. Y. Paget’s disease of bone. Clin. Endocr. Metab 1972; 1: 125-141.
- 14 Serafini A, Altman R, Sankey T. et al Paget’s disease: a method of evaluation of response to therapy using the Anger scintillation camera on-line to a computer (Abstract). J. Nucl. Med 1973; 14: 449.